As Chile prepares for the arrival of the southern hemisphere’s flu season, the government has once again turned to China to secure supplies of influenza vaccines, awarding a new contract to Sinovac Biotech. The agreement ensures millions of doses will be available in time for a nationwide immunisation campaign scheduled to begin in March, reinforcing Chile’s long-standing emphasis on preventive public health.
The decision marks the second consecutive year that Chile has sourced its influenza vaccines from Sinovac, reflecting continuity rather than urgency. Health officials say the move is part of a broader strategy to guarantee early access to vaccines and avoid shortages during peak flu months, when hospitals and clinics typically see a surge in respiratory illnesses. By finalising procurement well in advance, authorities aim to protect vulnerable populations before infection rates rise.
Chile’s public procurement agency for medicines and medical supplies, Cenabast, said the country’s immunisation programme is internationally recognised for its effectiveness, particularly among high-risk groups such as older adults, pregnant women, people with chronic conditions, and healthcare workers. Officials highlighted that consistent vaccination coverage has helped reduce hospitalisations and deaths linked to seasonal influenza in recent years.
The upcoming campaign will form part of Chile’s broader winter preparedness plan, which typically includes vaccination against influenza alongside other respiratory threats. Health authorities expect the flu vaccine to be offered free of charge through public health centres across the country, with outreach efforts focused on encouraging early participation. In past seasons, Chile has achieved relatively high uptake rates compared with many other countries in the region.
Sinovac, best known globally for its COVID-19 vaccines during the pandemic, has expanded its footprint in Latin America through long-term supply agreements and technology cooperation. Chile was among the countries that worked closely with the Chinese firm during the COVID-19 crisis, a relationship that has since evolved into more routine collaboration on seasonal vaccines. Analysts note that this continuity reflects trust built during previous public health emergencies rather than a shift driven by geopolitics.
For Chile, the choice of supplier is largely pragmatic. Securing reliable deliveries at competitive prices and on predictable timelines remains a top priority for public health planners. Officials stress that vaccine safety and efficacy standards remain aligned with international guidelines, regardless of the country of origin, and that all vaccines used in the programme undergo regulatory review before distribution.
The contract also underscores the growing role of Chinese pharmaceutical companies in global vaccine markets, particularly in emerging economies and the global south. As demand for seasonal vaccines increases worldwide, countries like Chile are seeking dependable partners that can scale production and meet tight delivery schedules.
With winter approaching, Chilean authorities hope the early rollout will help reduce pressure on the healthcare system and keep communities protected. The renewed partnership with Sinovac signals a focus on preparedness, stability, and public health outcomes rather than short-term political considerations.
